The efficacies of antifungal prophylaxis with ketoconazole and itraconazole, a new triazole, in patients with prolonged granulocytopenia were evaluated in two nonrandomized studies. The conditions other than the drug administered for prophylaxis were equivalent in the two studies. The incidence of fatal fungal infections was significantly higher among patients given ketoconazole than among those given itraconazole (P = .02); this trend was especially evident with fatal infections due to Aspergillus (P = .0045). The level of protection from fatal fungal infection afforded by itraconazole was higWy significant among patients who were granulocytopenic for more than 25 days (P < .0001) and among pa-
The efficacies of antifungal prophylaxis with ketoconazole and itraconazole, a new triazole, in patients with prolonged granulocytopenia were evaluated in two nonrandomized studies. The conditions other than the drug administered for prophylaxis were equivalent in the two studies. The incidence of fatal fungal infections was significantly higher among patients given ketoconazole than among those given itraconazole (P = .02); this trend was especially evident with fatal infections due to Aspergillus (P = .0045). The level of protection from fatal fungal infection afforded by itraconazole was higWy significant among patients who were granulocytopenic for more than 25 days (P < .0001) and among patients with acute lymphoblastic leukemia (P= .008). Failures of prophylaxis with itraconazole may have been due to inadequate levels of drug in plasma. Although these results must be interpreted with caution because they were obtained in consecutive nonrandomized studies, the use of itraconazole for antifungal prophylaxis in granulocytopenic patients seems to be a major advance and to be especially advantageous in hospitals, where the incidence of fatal aspergillosis in these patients is high.
Patients whose neutrophil counts are low are predisposed not only to bacterial infections but also to fungal infections, particularly with opportunistic fungi such as Candida and Aspergillus [1] . Fungal infections are promoted by antineoplastic agents [2] , corticosteriods, and drug-induced immunosuppression [3] . Moreover, as more effective antibiotics and better supportive measures become available, many patients who would have died of bacterial infections in the past will develop infections with more resistant organisms, such as fungi. The tissue damaged by the initial bacterial pathogen frequently serves as the nidus for fungal infection [4] .
Fungal infections in the immunocompromised patient are difficult to diagnose. Blood cultures are unrevealing in about one-half of the cases of proven invasive candidosis and are almost always negative in cases of invasive aspergillosis [5] . Conversely, Candida and Aspergillus may be isolated from various secretions when no invasive fungal infection is present because patients may be colonized with these organisms at many sites [5] .
This study was performed in accordance with the guidelines of the hospital's ethical committee.
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Presently, therapy for systemic candidosis and aspergillosis relies heavily on amphotericin B. Its poor tissue penetration and its potential for causing renal dysfunction, however, complicate its use [3] . Moreover, in patients with persistent granulocytopenia, results of therapy with amphotericin B for cases of proven invasive candidosis or aspergillosis are dismal, and many investigators have observed no difference between mortality rates in treated and nontreated patients [3] [4] [5] [6] , although a comparative study has never been carried out. Nevertheless, the empiric use of amphotericin B has been advocated for granulocytopenic patients who remain febrile after treatment with broad-spectrum antibiotics [7] [8] [9] , and it is hoped that this practice will improve the prognosis for febrile granulocytopenic patients. The extreme toxicity of amphotericin B remains a problem.
Prevention of invasive fungal disease in high-risk patients may be a valuable and less toxic alternative to treatment. Prophylaxis has been attempted with nystatin, oral amphotericin B, and -more recentlyketoconazole. Nystatin has been used for many years at various dosages without clear evidence of effectiveness [9] . Oral amphotericin B has been shown to reduce significantly the incidence of disseminated candidosis [10] . However, in a randomized study comparing ketoconazole with both oral amphotericin B and nystatin at conventional doses, ketocona-zole was found to be significantly more effective than either of the other agents in protecting the patient against superficial fungal infection [11] . Oral amphotericin B may be valuable in preventing invasive candidosis, since systemic candidosis most frequently originates in colonization of the gastrointestinal tract, with subsequent invasion by the organism through the severely altered mucosal membranes. This nonabsorbable drug cannot, however, be expected to prevent invasive aspergillosis, which is considered to be an airborne infection. Ketoconazole, on the other hand, is well absorbed but has only limited activity against Aspergillus species and nonalbicans species of Candida [12] . Itraconazole, a recently developed triazole, is well absorbed and has excellent in vitro and in vivo activity against both Aspergillus and nonalbicans species of Candida [13] .
We conducted two consecutive, nonrandomized studies of antifungal prophylaxis in severely granulocytopenic patients. The studies were conducted in two consecutive years; the first was of ketoconazole and the second of itraconazole. The conditions other than the drug administered for prophylaxis were the same in both years (e.g., hospital ward, use of reversed isolation procedures, cytotoxic and antimicrobial therapy).
Patients and Methods
A total of 97 patients with hematologic diseases were enrolled in the two studies. Sixty-six had acute myeloid leukemia (AML), 25 had acute lymphoblastic leukemia (ALL), two had severe aplastic anemia, two had a blast crisis of chronic myeloid leukemia, and two had non-Hodgkin's lymphoma. All patients except those with severe aplastic anemia received cytotoxic chemotherapy that resulted in prolonged granulocytopenia; those with aplastic anemia were treated with antithymocyte globulin. All patients were cared for in eight single rooms in which reversed isolation procedures were used. They received a low-bacteria diet and antimicrobial prophylaxis with nalidixic acid (four doses of 500 mg each per day), neomycin (four doses of 250 mg each per day), and colimycin (four doses of 10 6 units each per day). The patients' rooms were cleaned properly every day but lacked air conditioning and filtered air. They were situated in an old wing of the hospital, and during both study periods patients and materials were being moved from other patient-housing units to a new hospital. Patients who had undergone bone marrow transplantation were excluded from these studies because they were cared for in rooms with laminar airflow; none developed fungal infections while residing in these rooms. Two patients who received intensive cytotoxic chemotherapy during the itraconazole study were excluded from the analysis because they were given ketoconazole by mistake.
All patients with <0.5 x lQ6 granulocytes/ml who developed a fever of >38.5°C that persisted for at least 4 hr in the absence of recent transfusions were given broad-spectrum antibiotics (daily dosage: vancomycin, four doses of 500 mg each; cefuroxime, Table 3 . Incidence of proven and suspected fungal infections requiring therapy with amphotericin B among severely granulocytopenic patients given ketoconazole or itraconazole prophylaxis.
Results
The median duration of granulocytopenia (granulocytes, <0.05 x 10 6 /ml) among patients in the ketoconazole group was 26.5 days (range, 12-70 days); among those in the itraconazole group, it was 28 days (range, 8-57 days). The distribution of granulocytopenic periods of various lengths is summarized in table 2. In the ketoconazole group, 26 (50070) and 5 (9.5%) of the patients, respectively, experienced complete and partial remission of hematologic disease, and 21 (40%) died of infection and/or bleeding. In the itraconazole group, 31 (69%) and 3 (7%) of the patients, respectively, experienced complete and partial remission of hematologic disease, and 11 (24%) died of infection and/or bleeding. The difference in the rates of complete remission for the two groups barely failed to reach significance (P = .067). The cause of death in the patients given ketoconazole prophylaxis was fungal infection in 19 (36.5%), bacterial infection in 1 (2%), and bleeding in 1 (2%). The cause of death in the patients given itraconazole prophylaxis was fungal infection in 7 (15.5%), bacterial infection in 3 (6.5%), and bleeding in 1 (2%). The difference in mortality rates due to fungal infection for the two groups was significant (P = .02).
The number of patients with proven or suspected fungal infection who required parenteral treatment four doses of 1.5 g each; and amikacin, three doses of 750 mg each). Broad-spectrum antibiotics were administered to 51 of the 52 patients receiving ketoconazole and to 42 of the 45 receiving itraconazole. Granulocytopenic patients with fever that persisted for more than one week despite treatment with broad-spectrum antibiotics received amphotericin B (1 mg/kg per day).
An autopsy was performed on all patients who died, and all sites suspected of being infected were cultured. The diagnosis of invasive fungal infection was based on the presence of tissue invasion by fungi either in autopsy material or in lung biopsy specimens and on a positive culture. Plasma levels were measured with use of high-performance liquid chromatography. For 42 of the patients who received itraconazole, plasma levels of drug were determined daily. Levels of >250 ng/ml were considered adequate. Patients whose plasma levels were <250 ng/ml for at least seven consecutive days during the observation period were considered to have inadequate levels of drug.
The X 2 test was used to determine P values for a comparison of independent populations [14J. All 19 fatal fungal infections in the patients who received ketoconazole were due to invasive Aspergillus species, whereas fatal infections in the patients who received itraconazole were due to invasive Aspergillus species in five cases, Torulopsis glabrata in one, and Fusarium species in one. The difference between mortality rates due to Aspergillus species for the two groups was highly significant (P = .0045). Nonfatal, proven fungal infections occurred in four patients in the ketoconazole group; three of these infections were due to Candida albicans and one to Candida krusei. Likewise, four patients in the itraconazole group had nonfatal, proven fungal infections, three of which were due to T. glabrata and one to Candida parapsilosis.
Among the patients younger than 30 years old, three (16.5070) of the 18 receiving ketoconazole and none of the 12 receiving itraconazole developed a fatal fungal infection (P = .255). Among the patients older than 30 years, 16 (47070) of the 34 receiving ketoconazole and 7 (21070) of the 33 receiving itraconazole died of invasive fungal infection (P = .04).
A highly significant positive correlation was found between the occurrence of fatal fungal infection and prolonged granulocytopenia (table 4) . Among the patients who were granulocytopenic for longer than 25 days, 16 (57070) of 28 who were receiving ketoconazole and only three (9070) of the 34 who were receiving itraconazole died of fungal infection (P< .0001). Mortality due to fungal infection was only slightly lower among patients with AML who were treated with itraconazole than among those who were treated with ketoconazole (23070 vs. 28070), whereas the corresponding difference among patients with ALL was significant (no cases vs. 50070; P = .008).
Plasma levels of drug were determined for 42 patients who received itraconazole; 21 patients had inadequate levels «250 ng/ml for at least seven consecutive days). Eleven patients with inadequate levels developed proven or suspected fungal infections (eight and three cases, respectively); for five (24070) of the 21 patients with inadequate drug levels, fungal infection was fatal (Aspergillus, four cases; T. glabrata, one). In contrast, only four (19070) of the 21 patients who maintained adequate levels of drug had proven or suspected fungal infection; two cases (9.5070) were fatal. One of the fatal infections in this group, a disseminated infection with Fusarium, was due to a strain that was resistant to itraconazole in vitro; the other fatal infection was invasive aspergillosis.
Discussion
The incidence of invasive aspergillosis among patients with acute leukemia has increased progressively, and this fungal infection is fatal in the majority of patients [1] . Aspergillus is ubiquitous in most parts of the world. Inhalation of spores is the most common mode of acquisition. Clustering of infections due to Aspergillus among patients with hematologic neoplasms has been attributed to contaminated air in old and insufficiently ventilated hospital wards, to contamination of hospital ventilation systems, and to the presence of building materials and construction sites near hospital wards [1, 6] .
In a recent study, prolonged granulocytopenia was identified as the major risk factor for invasive aspergillosis in patients with acute leukemia [15] . In that study the risk of developing invasive aspergillosis was 40070 among those patients who remained granulocytopenic for >26 days and was 70% among those who were granulocytopenic for >34 days.
Factors promoting invasive fungal infections in our patients who were given prophylactic antifungal agents were aggressive cytotoxic chemotherapy; prolonged granulocytopenia; corticosteroid therapy in patients with ALL, severe aplastic anemia, and nonHodgkin's lymphoma; inadequate isolation facilities in an old and insufficiently ventilated hospital ward; prolonged antibiotic therapy in almost every case; and constant removal of other patients and of materials to a new hospital. The 36.5% incidence of invasive aspergillosis among our patients given ketoconazole prophylactically is not surprising in light of these adverse factors and of a median duration of severe granulocytopenia of 26.5 days and is comparable to the incidence observed by Gerson et al. [15] .
Because of the high incidence of aspergillosis in our first study of prophylaxis (with ketoconazole) and the good activity of itraconazole against Aspergillus reported previously [13] , we decided to perform a second nonrandomized study of prophylaxis in which all patients received itraconazole. (To carry out a randomized comparison of ketoconazole vs. itraconazole for antifungal prophylaxis was considered unacceptable by the hospital ethical committee.) All conditions other than the drug given for antifungal prophylaxis were considered the same in the two groups of patients studied. The sex and age distributions, clinical diagnoses, median durations of aplasia, and percentages of patients receiving broadspectrum antibiotics were also comparable.
Tricot et al.
Mortality due to fungal infections was significantly lower among patients who received itraconazole than among those who received ketoconazole (P = .02), particularly in the group with invasive aspergillosis (P = .0045). Patients who most benefited from itraconazole prophylaxis were those older than 30 years (P = .04), those who were granulocytopenic for longer than 25 days (P < .0001), and those with ALL (P = .008)
Results from nonrandomized studies must be interpreted with caution. It could be argued that infections caused by Aspergillus species may occur in clusters and that it is therefore not surprising to find a lower or higher incidence of fatal aspergillosis during one particular period. Tho observations make this argument an unlikely explanation for our findings. First, two patients with AML in the second group studied were mistakenly given ketoconazole rather than itraconazole; both were excluded from analysis, but both died of invasive aspergillosis. During the same period, two patients who had undergone bone marrow transplantation and had been readmitted to the hospital with severe graft-vs.-host disease were cared for in the same rooms as were the patients enrolled in our studies. These patients, who had normal granulocyte counts and were thus not included in the itraconazole study, also developed fatal aspergillosis during therapy with ketoconazole. Second, during the itraconazole study, the incidence of fatal infections due to fungi that were sensitive to the drug in vitro -Le., Aspergillus, Candida, and T. glabrata -was reduced dramatically among patients whose plasma levels of drug were adequate but remained relatively high (25 %) among those whose levels were inadequate.
The difference between the incidences of fatal fungal infection in the latter two groups of patients raises an important question: Why were adequate levels of drug not attained and maintained in so many patients? In nongranulocytopenic patients, administration of 200 mg of itraconazole daily resulted in adequate levels within two days (authors' unpublished observations). We doubled this dose for our granulocytopenic patients, but plasma levels of drug were inadequate in 50% of cases. Systemic availability of the drug is optimal when itraconazole is taken with a meal (authors' unpublished observations); however, most of our patients ate nothing while undergoing cytotoxic chemotherapy, and frequent vomiting, which results in inadequate drug intake, is common in patients undergoing such ther-apy. Both factors are most pronounced in patients with AML, who receive antineoplastic drugs for 10 consecutive days. This situation may explain why patients with inadequate levels of itraconazole in our study -and, consequently, most of those who died of fungal infection -were AML patients. Administration of itraconazole intravenously when the patient is receiving cytotoxic chemotherapy may overcome this problem and further reduce the incidence of fungal infections in granulocytopenic patients.
